LillyDirect and Manufacturer DTC Channels: How Telehealth Brands Should Position When Patients Can Buy Direct

Direct manufacturer access is no longer a press release. It is a channel.

For most of the GLP-1 era, manufacturer DTC felt like marketing.

A landing page. A coupon. A phone number to a partner pharmacy. Most patients still bought through a telehealth brand because access was easier there.

That has changed.

In 2026, manufacturer DTC channels are real distribution. They have:

their own checkout
their own pharmacy fulfillment
their own self-pay pricing
their own patient support
their own affiliate and broker programs
direct relationships with telehealth providers and prescribers
direct relationships with employer benefits platforms

Patients can now get an approved GLP-1, an approved hair loss medication, an approved ED treatment, an approved migraine drug, and several other branded products with a prescription routed straight to a manufacturer pharmacy.

The molecule is no longer a moat.

That sounds like a problem for DTC telehealth brands.

It is not, if you reposition correctly.

The brands that struggle in 2026 will be the ones whose entire value was "we can get you the drug." The brands that grow will be the ones whose value is the program around the drug.

What manufacturer DTC channels actually do in 2026

It helps to be precise about what is changing and what is not.

Most manufacturer DTC channels share a similar pattern:

a branded patient-facing site
a self-pay price for select products
a pharmacy fulfillment partner
a way for the patient to bring a prescription from any licensed prescriber
in some cases, a routed telehealth visit through a partner network
patient education tied to the manufacturer's label and indication

What manufacturer DTC channels usually do not do:

run your patient's full care plan
coordinate across multiple medications
manage lab review and ordering
handle prior authorization end to end
monitor side effects, dose changes, or pauses
handle complex billing across products and add-ons
own the long-term clinical and retention relationship

In other words, manufacturers are very good at access to a specific product.

They are not in the business of running a multi-condition care program for a patient.

That is where the DTC telehealth brand still has room to win.

Treatments

Example GLP-1 Treatments We Can Launch

View all

The wrong reaction: compete on price alone

The first instinct when a manufacturer goes direct is to drop prices.

That works for one quarter.

After that:

the manufacturer can move price faster than you can
the manufacturer has fewer middle layers
the manufacturer's brand recognition is higher
the manufacturer can afford to lose money on access to grow the molecule
your unit economics get worse just as your acquisition cost gets harder

A price-only response also trains patients to see your brand as a transactional resale.

That is the worst possible identity when a competitor with lower cost of goods enters the same shelf.

The right reaction is not to compete on the molecule.

It is to compete on what only the platform can deliver: program design, coordination, and clinical continuity.

The right reaction: reposition around the program, not the molecule

A useful way to think about this is to separate the patient journey into layers and ask which layer the manufacturer can or cannot own.

Journey layer	Can manufacturer DTC own it?	Where the DTC telehealth brand wins
Brand awareness	Yes	Trust, specialty, voice
Pricing on a single product	Yes	Bundles, savings across programs
Intake and eligibility	Partially	Multi-program intake, clinical depth
Provider review	Partially	Continuity, named clinician
Prescription to a manufacturer pharmacy	Yes	N/A
Multi-product care plan	No	Combinations, sequencing, switches
Lab ordering and review	No	Owned lab workflow
Side-effect and dose support	Limited	Full care team, structured monitoring
Subscription and billing	Partially	Multi-SKU, pause, swap, refund logic
Retention and outcomes	No	PRO collection, long-term outcomes
Adjacent program expansion	No	Hair loss, sexual health, menopause, peptides

The brands that win in 2026 will sound less like an online pharmacy and more like a care program.

That distinction is what allows price-sensitive patients to still choose you.

Where the DTC telehealth brand still beats manufacturer direct

It is worth being concrete about the wins.

1. Multi-product and multi-condition care

Manufacturers sell their own portfolio.

Your platform can prescribe and coordinate across multiple manufacturers, products, and indications.

A patient on a GLP-1 may also need:

hair loss treatment
migraine prevention
sleep apnea support
mental health care
sexual health support
hormone therapy
dermatology
general primary care

If your brand can carry the patient across those programs with one chart and one care team, no manufacturer DTC can match that.

2. Switching, sequencing, and combinations

A manufacturer-owned channel is unlikely to recommend switching the patient to a competitor's product.

Your platform can.

If a patient does not tolerate semaglutide, you can route them to tirzepatide. If oral does not work, you can route them to injectable. If a peptide is more appropriate, you can offer it.

That flexibility is a clinical and retention advantage.

For context on the wider product set, see New GLP-1 Products in 2026: The Telehealth Product Map.

3. Lab ordering and review

Manufacturer DTC channels do not own labs.

Telehealth platforms that order, review, and follow up on labs have a much stronger clinical story for any chronic program.

For deeper context on the lab workflow, see Telehealth Lab Workflow Design: Preventing Drop-Off Between Order, Completion, and Review.

4. Side effects, dose changes, and pauses

A patient on a serious medication needs more than a refill button.

They need:

a place to message a provider
structured side-effect intake
dose adjustment workflows
pause and resume logic
escalation to a clinician when needed

That is operationally hard.

It is also exactly the kind of value a manufacturer pharmacy is not built to provide.

5. Subscription and bundle economics

Manufacturer pricing is single-SKU.

Your platform can build:

multi-product subscriptions
starter and maintenance plans
annual prepay options
bundled lab, medication, and check-in pricing
pause and rejoin pricing
loyalty pricing for long-term patients

This is where billing engineering becomes a real moat.

6. Care continuity and named providers

Patients value seeing the same clinical team over time.

Manufacturer channels rotate prescribers through partner networks.

A DTC brand with provider continuity, structured charting, and patient portal messaging has a different relationship with the patient over twelve months.

For more on this, see Provider Network vs. Your Own Clinicians: How DTC Telehealth Brands Should Decide.

7. Multilingual and accessibility coverage

Manufacturer DTC channels are usually English-first.

DTC brands that invested in multilingual intake and accessible portals serve markets the manufacturer often does not.

What changes inside your intake when patients have manufacturer DTC as an option

If your intake still says "the only way to get this medication is through us," it is now misleading.

Patients increasingly know there are direct channels.

Stronger intake design acknowledges that, and uses it.

Update the intake to capture:

whether the patient has previously bought direct from a manufacturer pharmacy
whether the patient currently has a prescription from another provider
whether the patient is looking for medication access only or full program care
whether the patient is comparing price, program, or speed
whether the patient is on or considering switching products

This is not just market research.

It is clinical context that improves provider review and shapes which program path the patient is offered.

What changes inside your provider review

Provider review used to assume the patient was buying the medication through the brand.

In 2026, that is not always the case.

Some patients will arrive wanting:

a prescription routed to a manufacturer pharmacy
a second opinion on a manufacturer DTC prescription
a switch from a manufacturer product to another product
ongoing care after starting through a manufacturer channel
lab review for a medication they did not get through you

Provider workflows should support all of these without breaking.

That means:

letting providers route prescriptions to multiple pharmacy partners
letting providers continue care for patients who started elsewhere
letting providers document that the patient is on a manufacturer-direct script
letting providers update the care plan if the patient swaps channels mid-program

A brittle workflow that only supports your in-house pharmacy will lose patients to channels that support theirs.

What changes inside your billing

When a manufacturer DTC channel exists at a lower self-pay price, your billing has to do more than charge.

It has to explain.

Strong billing UX in 2026 should make clear:

what the patient is paying for if not the molecule
what is included beyond medication (program, provider, labs, support)
how the program price compares to medication-only access
what is refundable if treatment is not approved
how to pause, swap, or cancel without friction
how add-ons are priced
how price changes are communicated

If the patient cannot articulate why they are paying you instead of the manufacturer, they will leave.

Strong messaging in the billing flow can keep them.

For more on this, see Billing UX in Telehealth: What Patients Need to See Before the First Renewal.

What changes inside your patient communications

Marketing language that used to work no longer does.

Phrases like:

"the easiest way to get [drug]"
"approved in minutes"
"lower price than anywhere else"

are weaker now.

Stronger language emphasizes:

the program, not the molecule
the clinical team
the continuity of care
the breadth of conditions you can serve
the patient outcomes you can document
the support layer the patient gets beyond medication

This is a brand identity shift, not just a copy refresh.

A repositioning checklist for the next 90 days

Use this as a sprint plan, not a wish list.

Strategy and pricing

Audit current value claims - Which still hold when the manufacturer sells direct?
Map the price gap - What is the patient paying you that the manufacturer does not include?
Define program bundles - Medication plus what (labs, provider, portal, support)?
Set policy on manufacturer-direct prescriptions - Will you continue care for patients on a direct script?
Define adjacent programs - Which conditions can you also serve for the same patient?

Intake and routing

Add direct-channel awareness - Ask whether the patient is buying direct elsewhere.
Add switch and continuation flows - Support new starts, continuations, and switches.
Surface program value - Make clear what the platform provides beyond access.
Update pharmacy preference capture - Allow the patient to express a pharmacy preference.

Provider workflow

Multi-pharmacy routing - Providers can route to in-house, partner, or manufacturer pharmacies.
Continuation care - Providers can continue care for patients who started elsewhere.
Chart context - Provider notes include direct-channel history.
Switch documentation - Provider notes capture switches and reasons clearly.

Billing and packaging

Program pricing - Separate medication cost from program cost where possible.
Renewal messaging - Patients see what they get for the renewal before charge.
Pause and resume - Patients can pause without canceling.
Refund clarity - Clear refund rules for unfilled prescriptions and unused months.

Support and retention

Comparison content - Help patients understand the trade-offs honestly.
Outcome tracking - Collect structured outcomes you can show as proof of value.
Multi-program upsells - Offer adjacent programs when clinically appropriate.
Win-back flows - Patients who left to direct can come back for a full program.

Channel mix decisions: which patients should you serve

You do not have to win every patient.

You probably should not try to.

A clean way to think about target patients in a direct-access world:

Patient profile	Likely best channel	Implication for your brand
Price-sensitive, single product, knows what they want	Manufacturer DTC	Do not over-invest in winning
Wants a clinical team, multiple programs, continuity	DTC telehealth brand	Core target
New to the category, needs guidance and education	DTC telehealth brand	Strong target if education is good
Wants pharmacy speed, has a prescriber already	Manufacturer DTC	Partial target if you can offer continuation
Has comorbidities, complex history	DTC telehealth brand	Strong target with deep intake
Employer-sponsored access	Benefits platform	Possible B2B2C partnership
Wants oral options, switching, or dose adjustments	DTC telehealth brand	Strong target for flexibility

Once you know which patients you are best positioned to serve, your acquisition strategy gets cleaner.

You stop bidding on top-of-funnel keywords where the manufacturer will outspend you.

You start investing in content, programs, and audiences where the platform has a clear advantage.

For context on the wider distribution landscape, see GLP-1 Access in 2026: How Self-Pay, Direct Channels, and Telehealth Distribution Are Reshaping the Market.

Working with manufacturer DTC channels, not just against them

Some of the strongest 2026 strategies treat manufacturer DTC as a partner, not an enemy.

Possible plays:

become a verified telehealth provider that routes scripts to the manufacturer pharmacy
accept patients who started direct and need ongoing care
co-market education with the manufacturer for the specific molecule
integrate with the manufacturer's coupon or savings program
align on outcomes data and patient reporting
combine the manufacturer's price with your program for a stronger bundle

This works best when the manufacturer recognizes that telehealth brands extend the patient's relationship beyond what their channel does.

It does not work when either side is trying to be the only path.

Risks if you do not reposition

A few patterns to avoid.

Becoming a price reseller

If your only differentiator becomes price, you will lose. The manufacturer can usually go lower than you can.

Hiding the alternative

Patients will find out about direct channels. A brand that pretends they do not exist looks less trustworthy, not more.

Over-promising clinical depth

If you reposition as a "program" without actually building lab, provider, and support depth, the patient will see through it.

Ignoring adjacent programs

If your only revenue is from one molecule, your business shrinks the moment direct access lowers its price.

Treating retention as a billing feature

Retention is a clinical, support, and outcomes feature. Billing tools help, but they do not replace continuity of care.

For context on retention specifically, see Subscription Design in Telehealth Programs: What Improves Retention and What Creates Churn.

Final takeaways

LillyDirect, Pfizer for You, and other manufacturer DTC channels are not a threat.

They are a reality.

The DTC telehealth brands that grow in 2026 will:

stop selling the molecule and start selling the program
accept that manufacturer access is real and design for it
update intake, provider, billing, and support to acknowledge it
expand into adjacent conditions for the same patient
invest in lab, continuity, and outcomes the manufacturer cannot match
price the program clearly so the patient understands what they are buying
partner where it makes sense, compete where it does not

The brands that struggle will keep talking about the medication.

The brands that grow will start talking about the care.

That is the repositioning that turns direct access from a competitive threat into a clarifying force.